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Abstract
Background: Stem cell therapies have been widely investigated for their healing effects. However, the translation
of these therapies has been hampered by the requirement to deliver live allogeneic or autologous cells directly to
the wound in a clinical setting. Multipotent adult progenitor cells (MAPC® cells) are a subpopulation of bone
marrow-derived adherent stem cells that secrete a wide range of factors known to accelerate the wound healing
process. The aim of this study was to determine the impact of MAPC cells secretome on healing outcomes without
the presence of MAPC cells.
Methods: The effect of MAPC-conditioned medium (MAPC-CM) on the capacity of keratinocytes, fibroblasts and
endothelial cells to migrate and proliferate was determined in vitro using scratch wound closure and WST1 assay,
respectively. The effect of MAPC-CM on collagen deposition and angiogenesis was also assessed using in vitro
methods. Additionally, two excisional wounds were created on the dorsal surface of mice (n = 8/group) and 100 μL
of 20× MAPC-CM were intradermally injected to the wound margins. Wound tissues were collected at 3, 7 and 14
days post-wounding and stained with H&E for microscopic analysis. Immunohistochemistry was performed to
investigate inflammation, angiogenesis and collagen deposition in the wounds.
Results: Skin fibroblasts, keratinocytes and endothelial cells treated with MAPC-CM all showed improved rates of
scratch closure and increased cellular proliferation. Moreover, fibroblasts treated with MAPC-CM deposited more
collagens I and III and endothelial cells treated with MAPC-CM showed increased capillary tube formation. Murine
excisional wounds intradermally injected with MAPC-CM showed a significant reduction in the wound area and an
increase in the rate of reepithelialisation. The results also showed that inflammatory cell infiltration was decreased
while an increase in angiogenesis, as well as collagens I and III expressions, was observed.
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Conclusion: These findings suggest that factors produced by MAPC cells can have an important effect on
cutaneous wound healing by affecting skin cell proliferation and migration, balancing inflammation and improving
the formation of extracellular matrix and angiogenesis. Development of stem cell-free therapy for the treatment of
wounds may be a more clinically translatable approach for improving healing outcomes.
Keywords: Wound healing, Multipotent adult progenitor cells, Secretome, Conditioned medium, Inflammation,
Angiogenesis
Introduction
Wound healing is a well-coordinated process in which
various cell types receive external signals causing them
to proliferate, migrate, differentiate and synthesise pro-
teins to restore the multilayered tissue of skin [1]. Dur-
ing wound healing, fibroblasts from the surrounding
dermal layer proliferate and migrate into the wound site.
Fibroblasts in the wound area deposit extracellular
matrix (ECM) into the wound bed, which results in the
formation of new granulation tissue [2]. Simultaneously,
endothelial cells migrate into the wound bed and create
tube-like structures, which form the foundation of new
blood vessels. Finally, the skin barrier is restored during
the re-epithelialisation process where keratinocytes pro-
liferate and migrate across the wound bed to form the
neo-epidermis [3]. Any dysfunction in the cutaneous
wound healing process such as prolonged inflammation,
delayed proliferation and/or excessive collagen depos-
ition results in the formation of chronic wounds and
additional scarring in human adults [4].
Therapeutic potential of stem cells has been investi-
gated for the repair and regeneration of damaged tissues
and both preclinical and clinical trials have shown great
promise for the use of stem cells in wound healing im-
provement [5, 6]. However, the development of stem cell
therapies for the treatment of wounds has been ham-
pered by the requirement to deliver large numbers of
live, functional cells to patients [7].
Stem cell differentiation and direct incorporation into
regenerating tissues were speculated to be the primary
mechanisms of mesenchymal stem cell (MSC) actions
[8]. However, several cases have demonstrated that fre-
quency of stem cell engraftment and the number of
newly generated cells, either by differentiation or by cell
fusion, appears to be too low to explain significant ef-
fects achieved by stem cells [9]. Proteomic analysis of
stem cell conditioned media indicates that stem cells se-
crete a wide range of biomolecules which can contribute
to tissue regeneration including mRNAs, active lipids,
growth factors and cytokines [10]. Therefore, the para-
crine signalling of stem cells has been suggested as the
main mechanism for the actions of stem cells [9]. Evi-
dence from several in vitro and in vivo studies suggest
that beneficial effects of stem cell therapies on wound
healing are achieved via their paracrine effects on skin
cells. This increases the rate of proliferation and migra-
tion and functionality in resident immune cells, kerati-
nocytes, fibroblasts and endothelial cells [11].
Multipotent adult progenitor cells (MAPC cells) are a
sub-set of adherent stem cells that have outstanding
plasticity and self-renew ability [12]. These cells initially
were derived from adult bone marrow [12] but have also
been isolated from brain and muscle tissues [13]. In
comparison with MSCs, MAPC cells have been consid-
ered as a more biologically primitive population with
greater differentiation and proliferation potential [14].
Previously published studies have confirmed MAPC cells
as a distinct cell-type separate from MSCs with different
phenotype, function, differentiation and expansion cap-
acity, required culture conditions and transcriptional
profile [12, 15–17]. Furthermore, MAPC cells and MSCs
possess distinct secretomes based on their surrounding
environments [18]. Analysis of these secretomes has
demonstrated that MAPC cells respond to various stim-
uli by secreting a wide range of growth factors and cyto-
kines which affect processes such as angiogenesis,
immune function, fibrosis, and apoptosis, all key pro-
cesses during wound healing [19].
This paper aimed to investigate whether human
MAPC-conditioned medium (MAPC-CM) could accel-
erate cutaneous wound healing in vitro and in vivo. First,
proteins secreted by MAPC cells were identified using a
bead array assay. Second, the effect of MAPC-CM on
proliferation, migration and functionality of cutaneous
cells including keratinocytes, fibroblasts and endothelial
cells was determined using in vitro methods. Finally, the
effect of MAPC-CM on excisional wound healing was
investigated using a murine wound healing model. In
order to evaluate this effect, macroscopic and micro-
scopic assessments were employed. Moreover, the im-
pact of this treatment on inflammation, angiogenesis




Human MAPC cells were provided by ReGenesys BVBA
(Heverlee, Belgium). MAPC cells were isolated from a
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single bone marrow aspirate, obtained with consent from a
healthy donor and subsequently expanded on a Quantum
cell expansion system (Terumo BCT, Lakewood, USA) ac-
cording to previously described methods [16]. Cells were
further expanded on fibronectin-coated plastic tissue cul-
ture flasks. Cell cultures were maintained under low oxygen
tension in a humidified atmosphere of 5% CO2. Cells were
cultured to sub-confluence in MAPC culture media (low-
glucose DMEM (Thermo Fisher Scientific, VIC, Australia)
supplemented with foetal bovine serum (FBS, Atlas Biologi-
cals, Fort Collins, USA), ITS liquid media supplement
(Sigma-Aldrich, NSW, Australia), MCDB (Sigma-Aldrich,
NSW, Australia), platelet-derived growth factor (R&D Sys-
tems, Minneapolis, USA), epidermal growth factor (R&D
Systems), dexamethasone (Sigma-Aldrich, NSW, Australia),
penicillin/streptomycin (Invitrogen, CA, USA), 2-Phospho-
L-ascorbic acid (Sigma-Aldrich, NSW, Australia) and lino-
leic acid–albumin (Invitrogen, CA, USA)). Cells were pas-
saged every 3–4 days and harvested using trypsin/EDTA
(Invitrogen, CA, USA). Transcriptome analysis confirmed
that MAPC cells are distinct cell population from MSCs at
the point of use (Supplementary Information and Fig. S1).
Human foreskin fibroblasts (HFFs, CellBank Australia,
NSW, Australia) and human immortalised keratinocytes
(HaCaTs, ATCC, Virginia, USA) were cultured in low-
glucose DMEM medium (Thermo Fisher Scientific, VIC,
Australia) with 2 mML-glutamine, 10% FBS (Thermo
Fisher Scientific, VIC, Australia) and 100 U/mL penicil-
lin/streptomycin (Lonza, Basel, Switzerland). Human
dermal microvascular endothelial cells (HDMECs, Pro-
moCell, Heidelberg, Germany) were grown in endothe-
lial cell growth medium MV2 (PromoCell, Heidelberg,
Germany) with 2 mML-glutamine, 10% FBS and 100 U/
mL penicillin/streptomycin (Lonza, Basel, Switzerland).
These three cell types were incubated at 5% CO2, 37 °C
and 95% humidity.
MAPC-conditioned medium collection
To harvest MAPC-CM, 2 × 103 cells per cm2 were
seeded into T75 flasks. Upon reaching 70% confluency,
MAPC medium was removed, flasks were washed twice
with phosphate-buffered saline (PBS) and 10mL FBS-
free DMEM medium was added to the flasks. Following
24 h incubation under hypoxia conditions, the condi-
tioned medium was collected from each flask. To obtain
consistent small batches of CM, the conditioned media
of MAPC cells in 20 flasks were combined, centrifuged
at 350 g for 10 min and sterilised using 0.22 μm filters.
For in vivo applications, the conditioned medium was
concentrated 20× using GE Vivaspin™ protein concentra-
tor spin columns (Bio-strategy, VIC, Australia). Aliquots
were kept in − 80 °C freezer until use. In all experiments,
fresh FBS-supplemented DMEM with 10% FBS was used
as the positive control while fresh FBS-free DMEM
medium was used as the negative control.
Bead array assay
A bead-based immunoassay was employed to detect and
quantify the concentration of soluble proteins in MAPC-
CM including growth factors, adhesion molecules and
inflammatory cytokines. The experiment was performed
according to the manufacturer’s protocols (BioLegend’s
LEGENDplex™, CA, USA). Briefly, human MAPC cells
were cultured for at least two passages under normal
culture conditions. Prior to the collection of conditioned
medium, MAPC cells (75–85% confluent) were cultured
in FBS-free DMEM for 24 h in the absence of any ex-
ogenous stimuli. Then, the collected conditioned
medium was concentrated 20× using GE Vivaspin™ pro-
tein concentrator spin columns. Concentrated condi-
tioned medium and standards were incubated with
antibody-conjugated capture beads for each protein for
2 h with shaking. Following binding of the capture beads
with their target proteins, biotinylated detection anti-
bodies were added to the wells and incubated for an
hour with shaking. Streptavidin phycoerythrin (SA-PE)
was added to the wells and incubated for 30 min. After
washing with SA-PE, the wells were loaded with wash
buffer and read using a BD LSRFortessa™ flow cytometer
(BD Bioscience, CA, USA).
Cell proliferation assay
The effect of MAPC-CM on the proliferation of HFFs,
HaCaTs and HDMECs was analysed using the WST-1 (2-
(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium monosodium salt) proliferation assay according
to the manufacturer’s protocols (Roche Applied Science,
Bavaria, Germany). In brief, cells were plated onto 96-well
plates at the density of 5 × 103 cells/well in their own rec-
ommended culture conditions. When they reached 25–35%
confluence, cells were washed with PBS to remove media
and the media were replaced with either FBS-free DMEM
(negative control), DMEM with 10% FBS (positive control)
or MAPC-CM. Following 24 h incubation, WST-1 (10%)
was added to each plate and the absorbance was measured
at 460 nm using a microplate reader (Tecan Group,
Mannedorf, Switzerland).
Scratch wound closure assay
Migration of dermal fibroblasts, keratinocytes and endo-
thelial cells in MAPC-CM was assessed using a scratch
wound closure assay. To conduct this assay, cells were
seeded onto 96-well plates at the density of 3 × 104 cells/
well in their own recommended media and maintained
until reaching 80–90% confluency. Cell monolayers were
scratched using a wound maker™ (Essen bioscience, MI,
USA). After scratching, wells were washed twice using
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PBS and their culture media was replaced with either
FBS-free DMEM (negative control), DMEM with 10%
FBS (positive control) or MAPC-CM. Plates were then
placed in the IncuCyte (Essen bioscience, MI, USA) to
record the scratch wound closure by taking images im-
mediately after scratching and every 3 h until complete
wound closure. For the study on the MAPC-CM, the
remaining scratch area of each well was calculated and
presented as the extent of wound closure.
Collagen I and III staining of fibroblasts
Collagens I and III were determined using a 96-well im-
munohistochemistry assay [20]. HFFs were seeded in
DMEM with 10% FBS at 5 × 104 cells/well into 96-well
plates. The medium was replaced with test reagents after
24 h. Plates were left in the incubator for 60 h to allow
collagens to be deposited. Cells were washed with PBS,
fixed and permeabilised in ice-cold methanol (− 20 °C).
Cells were then treated with Tween 20 (0.5%) in PBS for
10 min before incubating in 3% normal goat serum
(NGS, Thermo Fisher Scientific, VIC, Australia) for
30 min and finally incubating with rabbit anti-human
collagen type I antibody (5 μg/mL, Rockland Immuno-
chemicals, USA) and rabbit anti-human collagen type
III Antibody (5 μg/mL, Rockland Immunochemicals,
USA) at room temperature for 2 h. Secondary anti-
body goat anti-rabbit IgG Alexa Fluor 488 (5 μg/mL,
Invitrogen, CA, USA) was added to cells for an hour.
Nuclear fluorescent dye (DAPI, (4′, 6-diamidino-2-
phenylindole)) was added prior to imaging. The plate
was then imaged using an Olympus IX83 fluorescence
microscope and the fluorescence intensity of the wells
was measured in order to determine the expression of
collagens I and III.
Matrigel tube formation assay
An in vitro tube formation assay was employed in order
to examine the possible effect of MAPC-CM on blood
vessel formation. This assay investigates the ability of
human endothelial cells to form tube-like networks and
tube sprouts after incubation in MAPC-CM. Ten micro-
litres growth factor reduced Matrigel (Corning Life Sci-
ence, New York, USA) was added to each well of Ibidi
u-slide angiogenesis 15-well plates (ibidi GmbH, Bavaria,
Germany), which then was incubated at 37 °C for 30
min. HDMECs (1.5 × 104) suspended in 50 μL of either
FBS-free DMEM (negative control), DMEM with 10%
FBS (positive control) or MAPC-CM were seeded in
each well and images were taken every 3 h using an
Olympus IX81 microscope (Olympus, Tokyo, Japan).
The number of tubes in each well was counted every 3 h
until all tubes were degraded.
Murine model of excisional wound healing
Female BALB/c mice 10–12 weeks old were used for the
study. Two 6mm2 full-thickness dorsal excisional
wounds were created 5 mm either side of the midline
and 10 mm from the base of the skull. One hundred
microlitres of 20× concentrated conditioned medium
was injected at four sites into the margins of each
wound. One hundred microlitres FBS-free DMEM was
injected at four sites into the margins of wounds in the
control group (n = 8/group). Digital photographs of the
wounds were taken for macroscopic analysis of wound
healing and wounds were harvested at days 3, 7 and 14
post-injury for histological and immunohistochemical
analysis.
Histological and immunohistochemistry analyses of
wound tissues
Histological sections (4 μm) from paraffin-embedded
fixed tissues were stained with haematoxylin and eosin
(H&E) for microscopic analysis of wound healing. The
sections were also stained with Masson’s trichrome stain
for total collagen analysis. Moreover, sections were sub-
jected to immunohistochemistry, similar to previous
studies [21], following antigen retrieval. Tissue sections
were blocked in 3% blocking NGS for 30 min at room
temperature, incubated with rabbit anti-human collagen
type I (5 μg/mL, Rockland Immunochemicals, Pennsylva-
nia, USA), rabbit anti-human collagen type III (5 μg/mL,
Rockland Immunochemicals, Pennsylvania, USA), rat
neutrophil marker (NIMP-R14, 0.5 μg/mL, Santa Cruz
Biotechnology, Texas, USA) and rabbit anti-CD31
(0.2 μg/mL, Abcam, Cambridge, UK), F4/80 (5 μg/mL,
Bio-Rad, NSW, Australia), YM-1 (0.37 μg/mL, StemCell
technologies, Vancouver, Canada) antibodies overnight
at 4 °C. Subsequently, tissue sections were stained with
secondary goat anti-rabbit IgG, Alexa Fluor 488, goat
anti-rabbit IgG, Alexa Fluor 568 or goat anti-rat IgG
Alexa Fluor 488 (5 μg/mL, Invitrogen, CA, USA). To
visualise nuclei and overall tissue architecture, sections
were stained for 5 min in 4′,6-diamidino-2-phenylindole
(DAPI, 1:5000 of 1 mg/mL stock). Sections were imaged
with Olympus IX81 microscope (Olympus, Tokyo,
Japan).
Statistical analysis
The results are presented as mean ± SEM. Data analysis
was performed using GraphPad Prism (Graphpad, CA,
USA). One-way and two-way analysis of variance
(ANOVA) tests were used for multiple comparisons
followed by Tukey and Bonferroni post-tests. Data are
representative of the means of at least three independent
experiments and values. A value of p < 0.05 was set for
the significance value.
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Results
Secretome analysis of MAPC cells and identification of
proteins correlated to wound healing
In order to identify proteins secreted into the condi-
tioned media by MAPC cells, bead array assays were
employed. This assay was conducted to quantify a num-
ber of proteins associated with wound healing including
growth factors, inflammatory cytokines and adhesion
molecules. The concentration of secreted proteins found
in conditioned media of MAPC cells is shown in Table 1
along with their role in wound healing. Note that no
protein was detected in FBS-free DMEM.
MAPC-CM increases the proliferation and migration of
fibroblasts, keratinocytes and endothelial cells
To measure the effect of MAPC-CM on skin cells prolif-
eration, a WST-1 assay was used. As shown in Fig. 1,
the proliferation of HaCaTs was significantly increased
by 17.4% following 24 h of treatment with MAPC-CM in
comparison to the FBS-free DMEM (negative control)
(Fig. 1a, d). Proliferation of MAPC-CM-treated HFFs
was also increased by 8.8% (Fig. 1b, e). HDMECs simi-
larly showed elevated proliferative ability with an in-
crease of 29.3% over the negative control (Fig. 1c, f).
In order to determine the effect of MAPC-CM on the
migration ability of skin cells, a scratch wound closure
assay was used. Migration of HaCaTs into the scratch
area was significantly enhanced from the first time point
(3 h) after scratch, while cells in FBS-free DMEM (nega-
tive control) had not started to migrate (Fig. 2a, d).
Migration of HaCaTs into the scratched area was signifi-
cantly increased at each time point compared to the
negative control. This increase was even significantly
higher than the DMEM + 10% FBS (positive control) at
each time point (Fig. 2a, d). Migration ability of HFFs
was also significantly enhanced following 9 h of treat-
ment with MAPC-CM compared to negative control
medium (Fig. 2b, e). Similarly, migration of HDMECs
was enhanced in the presence of MAPC-CM, which was
statistically significant 15 h after scratching (Fig. 2c, f).
MAPC-CM encourages tube formation of endothelial cells
and increases the halftime life of formed tubes
An in vitro tube formation assay was conducted in order
to examine the possible effects of MAPC-CM on blood
vessel formation. Tube formation of HDMECs was
quantified by counting the average number of tube-like
structures (Fig. 3a). HDMECs formed the maximum
number of blood vessel-like structures in all three
groups after 3 h after which tubes began to degrade. As
indicated in Fig. 3b, the average number of tube-like
structures in each time point was significantly higher in
HDMECs incubated with MAPC-CM compared with
those incubated with FBS-free DMEM (negative
control).
Degradation of tube-like structures began after 3 h,
with all structures in FBS-free DMEM (negative control)
and DMEM with 10% FBS (positive control) being de-
graded after 30 and 72 h, respectively. The overall num-
ber of tubes remained significantly elevated at each time
point in MAPC-CM wells, with a prolonged half-life of
tubes observed up to 96 h (Fig. 3b). These results indi-
cate the positive effect of MAPC-CM impact not only
on vessel formation but also on vessel stabilisation.
Table 1 MAPC cell protein secretome. Functionally distinct classes of molecules identified by bead array assays
ID/concentration (pg/mL) Description/function
ECM proteins Matrix metalloproteinase (MMP-1)/(29,838 ± 385) Involved in collagen degradation, ECM remodelling cell
migration [22] and angiogenesis [23].
Tissue inhibitor of metalloproteinase (TIMP-1)/(> 771,464) Inhibitor of MMPs and regulator of cell migration [22].
Growth factors and
modulatory proteins
Hepatocyte growth factor (HGF)/(1817 ± 38) Accelerates re-epithelialisation. Suppresses inflammation.
Promote angiogenesis [24]
Vascular endothelial growth factor (VEGF) (725 ± 42) Proangiogenic mediator [25].
Fibroblast growth factor-2 (FGF-2)/(172 ± 55) Promotes proliferation and migration of fibroblasts and
affect collagen deposition [26]. Contributes to the collagen
maturation [27].
Adhesion Molecules Vascular cell adhesion protein (VCAM-1)/(32,641 ± 1538) Cell adhesion molecule. Involves in inflammation, cell
proliferation and migration [28].
CD166 (ALCAM)/(89,555 ± 955) Regulator of T cells and MMP activity [29].
CD44/(9344 ± 938) Regulator of cell migration, survival and differentiation [30].
Inflammatory cytokines Monocyte Chemoattractant Protein-1 (MCP-1)/(17 ± 1) Controls the migration and recruitment of monocytes/
macrophages during inflammation [31].
Interleukins (IL): IL-8 (262 ± 110), IL-2 (21 ± 2), IL-1β (9 ± 0) Pro-inflammatory cytokines [32].
IL-6 (1150 ± 414) A pro-inflammatory cytokine and an anti-inflammatory
cytokine [33]
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MAPC-CM enhances collagens I and III deposition of
fibroblasts
In order to assess the potential effect of MAPC-CM on
collagen deposition, cultured HFFs were incubated with
MAPC-CM for 60 h prior to staining with collagen I or
collagen III antibodies. Cells stained immunocytochemi-
cally were imaged on a Zeus microscope (Olympus,
Tokyo, Japan) and analysed using cellSense software
(Fig. 4a). For intensity measurements, the mean grey in-
tensity value was measured across the well. Collagen I
and III expressions quantified as mean grey intensity
within the well. The intensity for collagen I was increased
by 1.2-fold in cells that were treated with MAPC-CM
compared to those that were incubated in FBS-free
DMEM (negative control) indicating a significant increase
in the collagen I deposition with MAPC-CM treatment
(Fig. 4b). The deposition of collagen III by fibroblasts was
elevated to 1.05-fold following MAPC-CM stimulation
compared to the negative control (Fig. 4c). In both cases,
deposition of collagens I and III in response to MAPC-
Fig. 1 Effect of MAPC-CM on the proliferation of skin cells. Representative images of all three skin cell types 24 h after treatment with MAPC-CM
versus negative control media. Cells are masked with confluency mask of Incucyte zoom software (a–c). The proliferation was quantified by WST-
1 assay which demonstrates increased proliferation in MAPC-CM-treated group compared to the negative control group in d HaCaTs, e HFFs and
f HDMECs. Values are mean ± SEM of 3 independent experiments. n = 6. Statistical significance calculated by one-way ANOVA followed by Tukey’s
test, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, ns = non-significant
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Fig. 2 Effect of MAPC-CM on the migration of skin cells. Representative images of scratch assays show scratches immediately after the scratches
had been made and then after 24 h in the presence of MAPC-CM versus positive and negative control media. The percentage signifies the extent
of wound closure 24 h after making scratches, compared to the initial scratch area and measured using Incucyte zoom and ImageJ software (a–
c). There was a significant increase in the extent of wound closure in MAPC-CM-treated group than in the negative control group in d HaCaTs, e
HFFs and f HDMECs. Values are mean ± SEM of 3 independent experiments. n = 6. Statistical significance calculated by one-way ANOVA followed
by Tukey’s test, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, ns = non-significant
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CM treatment were higher than FBS-containing DMEM
(positive control) (Fig. 4b, c).
The total number of cells, stained positive with DAPI
nuclear stain, were counted to assess the impact of HFF
proliferation on the amounts of collagens I and III. The
total number of HFFs either in collagen I or collagen III ex-
periment was not significantly different between the cells
incubated with MAPC-CM, FBS-free DMEM (negative
control) or DMEM with 10% FBS (positive control). This
non-significant difference was probably due to the contact
inhibition effect, which indicates that the increase in the
collagen deposition of HFFs was not due to a correspond-
ing increase in HFF numbers during culture (Fig. 4d, e).
MAPC-CM treatment improves wound healing in
excisional wounds
The effects of MAPC-CM on cutaneous repair and re-
epithelialisation was determined using an excisional murine
Fig. 3 Effect of MAPC-CM on in vitro tube formation. Representative images of HDMEC cells in tube-like structures, 24 h after seeding onto
Matrigel (a). MAPC-CM encouraged endothelial cells to reorganise into 3D vessel structures at each time point until 72 h (b). Values are mean ±
SEM of 3 independent experiments. n = 6. Statistical significance calculated by one-way ANOVA followed by Tukey test, where * = p < 0.05, ** =
p < 0.01, *** = p < 0.001, ns = non-significant
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wound healing model. Macroscopic analysis of wounds
treated with MAPC-CM showed a significant reduction in
average wound area compared to DMEM-treated wounds
(control groups) at days 3, 7 and 14 of healing (Fig. 5a, b).
Histological analysis of wound morphology in H&E-
stained paraffin-embedded wound tissues (Fig. 5c) also
showed decreased microscopic wound area (Fig. 5d) and
wound width (Fig. 5e) in MAPC-CM-treated wounds at
days 3, 7 and 14 of healing. Further analysis of H&E-
stained wound tissues at day 3 of healing revealed 15% re-
epithelialisation of the wounds in the MAPC-CM-treated
group compared with 6% in the control group. At day 7 of
healing, wounds in MAPC-CM-treated mice were 90% re-
epithelialised (Fig. 5f). In contrast, wounds from control
mice reached only 78% re-epithelialisation by day 7. At
day 14 of healing, all wounds in both MAPC-CM-treated
and control mice were fully re-epithelialised (Fig. 5f).
MAPC-CM treatment decreases inflammatory response in
excisional wounds
To explore the impact of MAPC-CM on inflammation,
immunofluorescent staining of neutrophil marker NIMP-
Fig. 4 Effect of MAPC-CM on collagens I and III production of HFFs. Representative images of HFFs treated with MAPC-CM versus positive and
negative control media stained for collagen I and collagen III (a). Fluorescence intensities measured using CellSens dimension software (version
1.12), which show that MAPC-CM increases collagens I and III production by HFFs (b, c). HFFs were also stained with DAPI and cell numbers in
each well were counted (d, e). Data are presented as mean ± SEM. n = 6. Statistical significance calculated by one-way ANOVA followed by
Tukey’s test, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, ns = non-significant
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R14 and macrophage marker F4/80 was carried out to
quantify neutrophil and macrophage infiltration into the
wound bed. Figure 6a shows fluorescence microscopy im-
ages of wounds, where the highest number of neutrophils
was observed at day 3 of healing. This is expected as infil-
tration of neutrophils begins at the early stages of the in-
flammatory phase [34]. Neutrophil numbers decreased at
days 7 and 14 of healing. This reduction can be explained
by the fact that immune cells undergo apoptosis to resolve
inflammation over the course of healing [34]. Quantifica-
tion of NIMP-R14-positive cells in the wound area indi-
cated less inflammatory cell infiltration to the wound bed
in MAPC-CM-treated mice compared to the control
group at days 3, 7 and 14 of healing (Fig. 6b). The quanti-
fication of macrophage infiltration using macrophage
marker (F4/80) demonstrated a decrease in the presence
of F4/80-positive macrophages in MAPC-CM-treated
wounds at day 7 (Fig. 6c, d). The percentage of M2 anti-
inflammatory macrophages expressing Ym-1 indicated
that the rate of polarisation of macrophages to an anti-
inflammatory state was increased by MAPC-CM treat-
ment at 7 days of healing (Fig. 6c, e).
MAPC-CM treatment increases endothelial cell number
and angiogenesis in excisional wounds
In order to investigate the effect of MAPC-CM on
angiogenesis, the tissues were immunostained with
endothelial cell marker, CD31 (Fig. 7a). The number of
CD31-positive endothelial cells and blood vessels was in-
creased from day 3 to day 7 but reduced at day 14. In-
creased numbers of CD31-positive endothelial cells in
MAPC-CM-treated wounds were observed at each time
point when compared to the control group (Fig. 7b). Ca-
pillary density, as measured by the number of mature
Fig. 5 Effect of MAPC-CM on the rate of excisional wound healing. Representative images of MAPC-CM treated and control wounds at days 3, 7
and 14 of healing (a). Analysis of images using Image Pro-Plus program demonstrates decreased macroscopic wound area in MAPC-CM-treated
wounds on days 3, 7 and 14 post-injury (b). Representative images of MAPC-CM-treated and control wounds sections after H&E staining at days
3, 7 and 14 of healing. Images captured at 10× objective. Black dashed lines indicate wound width measured (c). The histological analysis of
wounds demonstrates decreased microscopic wound area (d), wound width (e) and increased average re-epithelialisation (f) in MAPC-CM-treated
wounds. n = 8. All data is represented as mean ± SEM. Statistical significance calculated by two-way ANOVA followed by Bonferroni post-tests,
where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, ns = non-significant
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vessels per mm2, was also significantly increased in
MAPC-CM-treated wounds at days 7 and 14 of healing
(Fig. 7c).
MAPC-CM treatment elevates collagen expression in
excisional wounds
Masson’s trichrome staining was undertaken to measure
the total amount of collagen in wound tissues (Fig. 8a).
The analysis of stained sections revealed that total colla-
gen in MAPC-CM-treated wounds on day 7 and day 14
was elevated significantly compared to control wounds
(Fig. 8b).
In order to investigate the effect of MAPC-CM on the
expression of different collagen types, the wound tissues
were stained with collagen I and collagen III antibodies
(Fig. 8c). Results show that both collagens I and III ex-
pression was increased at day 7 in MAPC-CM-treated
wounds. Collagen I expression was also elevated in
MAPC-CM-treated wounds at day 14 of healing while
there was no significant difference in collagen III
Fig. 6 Effect of MAPC-CM on inflammation in excisional wounds. Representative images of immunofluorescent NIMP-R14 positive neutrophils
(green) counterstained with DAPI (blue) in wounds at days 3, 7 and 14 post-injury (a). Quantification of neutrophil numbers in the wound bed
normalised to wound area (b). Representative images of immunofluorescent macrophages by F4/80 (green) and YM-1 (red) staining
counterstained with DAPI (blue) in wounds (c). Quantification of total macrophage number (F4/80+) in the wound bed normalised to wound
area (d). Quantification of M2 macrophages (F4/80+, YM-1+) as a percentage of total macrophages in the wound bed normalised to the wound
area. Images captured at 20× objective. n = 8. All data is represented as mean ± SEM. Statistical significance calculated by two-way ANOVA
followed by Bonferroni post-tests, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, ns = non-significant
Ahangar et al. Stem Cell Research & Therapy          (2020) 11:299 Page 11 of 16
expression between two groups at day 14 of healing
(Fig. 8d, e).
Discussion
Over the last two decades, stem cells have been exten-
sively used in regenerative medicine due to their positive
effects on cardiac, bone and liver regeneration [7]. How-
ever, the clinical use of these cells is limited due to the
barriers that exist in utilising stem cells including low
differentiation capability, cellular senescence and limited
replicative lifespan. The translation of stem cell therapies
into clinical products has further been limited due to
low cell survival and poor engraftment, immunogenicity
and tumorigenicity of cells after administration [35] Re-
cent studies have suggested that stem cells secrete bio-
molecules into their environments that are beneficial for
inducing cell differentiation and functional responses
important for tissue repair [11].
Fig. 7 Effect of MAPC-CM on angiogenesis in excisional wounds. Representative images of immunofluorescent detection of endothelial cells and
blood vessels by CD31 staining (yellow) counterstained with DAPI (blue) at wounds. Images captured at 20× objective (a). Quantification of
endothelial cells in the wound bed normalised to the area (b). Quantification of blood vessels in the wound bed normalised to the area (c). n = 8.
All data is represented as mean ± SEM. Statistical significance calculated by two-way ANOVA followed by Bonferroni post-tests, where * = p < 0.05,
** = p < 0.01, *** = p < 0.001, ns = non-significant
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MSCs have been previously shown to have paracrine
effects on regulating angiogenesis, promoting tissue re-
modelling and recruiting other cells as well as having
immunomodulatory, anti-inflammatory and anti-fibrosis
effects [36–39]. Although MAPC cells and MSCs have
some similarities, in that both are bone marrow-derived
adherent and non-haematopoietic stem cells [14], their
secretome is different as the composition and thera-
peutic benefit of the secretome can be impacted by isola-
tion methods, culture and storage conditions [40].
In the present study, treatment of excisional wounds
with MAPC-secretome in the form of MAPC-CM led to
improved wound healing outcomes evidenced by de-
creased wound area, wound width and inflammatory cell
infiltration as well as increases re-epithelialisation. Fur-
thermore, MAPC-CM-treated wounds displayed reduced
inflammation, increased angiogenesis and increased
amounts of collagens I and III.
MAPC cells possess broader expansion capacities than
MSCs and do not show signs of cell senescence,
Fig. 8 Effect of MAPC-CM on total collagen production and collagens I and III expression in excisional wounds. Representative images of collagen
detection (green) by Masson’s trichrome staining Images captured at 10× objective (a). Quantification of total collagen levels in wound bed
normalised to the normal skin collagen (b). Representative images of immunofluorescent detection of collagen I and collagen III (green)
counterstained with DAPI. Images captured at 20× objective (c). Quantification of collagen I expression as mean grey intensity within the wound
bed and normalised to the normal skin collagen I level (d). Quantification of collagen III expression as mean grey intensity within the wound bed
and normalised to the normal skin collagen III level (e). Values are mean ± SEM of 3 independent experiments. n = 6. Statistical significance
calculated by two-way ANOVA followed by Bonferroni post-tests, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, ns = non-significant
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karyotypic abnormalities and telomere shortening [41];
these facilitate large scale production of MAPC cells and
MAPC-secretome for therapeutic treatment.
Previous studies have reported the effectiveness of live
MAPC cell treatment on wound healing in mice [42–44].
Herein, MAPC-CM is shown to be equally as effective as
MAPC cell treatment with macroscopic and histological
analyses of wound tissues confirming enhanced wound
closure time and increased rate of re-epithelialisation. This
is consistent with the in vitro studies showing a clear
beneficial effect of MAPC-CM on keratinocyte and fibro-
blast proliferation and migration. Analysis of MAPC-CM
suggests that its effect could be partly due to the presence
of secreted proteins that have a significant impact on the
proliferation and migration of keratinocytes and fibro-
blasts including FGF-2, MMP-1 and HGF [23].
MAPC cells have previously been reported to have im-
munomodulatory and anti-inflammatory potential both
in in vitro culture and in recipients [45]. In the present
study, the analysis of NIMP-R14-stained wound tissues
suggested there was reduced inflammation in the
MAPC-CM-treated wounds evidenced by a significant
reduction in neutrophilic infiltration. In addition, the
number of macrophages in wounds were also lower in
MAPC-CM-treated wounds. The polarisation of inflam-
matory M1 macrophages to anti-inflammatory M2 mac-
rophages was also promoted in MAPC-CM-treated
wounds. The anti-inflammatory effect may be explained
by the secretion of cytokines and growth factors by
MAPC cells into the conditioned media that contribute
to inflammatory cell infiltration and resolution. Analysis
of the bead array assays confirmed that MAPC-CM con-
tains high concentrations of inflammatory cytokines
mainly IL-6 (both pro and anti-inflammatory cytokine).
Our findings are also consistent with other studies that
have confirmed the secretion of various pro/anti-inflam-
matory cytokines including IL-6, IL-10, IL1α, IL8 and
TNFα by MAPC cells [19].
In the proliferation phase of wound healing, fibroblasts
migrate to the wound site and secrete components of
ECM mainly collagens I and III within the wound bed.
During the remodelling phase, the relative proportions
of collagens I and III changes (type I collagen content
increases while collagen type III decreases), and total
collagen content increases. These functions are all re-
quired for wound contraction [2, 46]. MAPC-CM was
found to contain secreted collagens, ECM proteins and
other growth factors which mediate ECM production
and remodelling [19]. In this study, we also have found
that the production of collagens I and III by dermal fi-
broblasts was augmented when they were treated with
MAPC-CM in vitro. Additionally, measuring collagen
expression in mice treated with MAPC-CM showed an
increase in the production of both collagen I and III at
day 7 and collagen I production at 14 post-injury while
there was no difference in the amount of collagen III at
day 14. This result confirmed the improvement of colla-
gen remodelling in MAPC-CM-treated wounds. This
improvement could be partly due to the presence of
FGF-2 in MAPC-CM, which has been shown to induce
collagen production [47].
Failure of neovascularization and angiogenesis is an-
other important factor which contributes to impaired
wound healing [48]. Our results revealed an increase in
proliferation and migration in endothelial cells in the
presence of MAPC-CM. Endothelial cells treated with
MAPC-CM also formed more vessel-like tubes than un-
treated ones. Furthermore, formed tubes persisted in cul-
ture for longer when treated with MAPC-CM. Accordingly,
the number of endothelial cells and blood vessels was also
increased in MAPC-CM-treated wounds which shows the
significant effects of MAPC-CM on angiogenesis and
wound healing. The number of endothelial cells and blood
vessels were increased in MAPC-CM-treated wounds
which shows the significant effects of MAPC-CM on angio-
genesis and wound healing. We also showed that MAPC-
CM contains VEGF which is a proangiogenic factor with
an ability to stimulate proliferation, migration and vessel
formation of endothelial cells [19, 49].
Overall, histological and immunohistochemistry obser-
vations, taken together with the morphometric parame-
ters, demonstrated that wounds treated with MAPC-CM
show improved healing responses. This improvement
was mediated through a combination of reduced inflam-
mation and enhanced re-epithelialisation, angiogenesis
and collagen production. This study suggests the use of
MAPC-CM as a promising alternative to stem cell-based
therapies for the treatment of wounds.
Conclusion
Intradermal administration of MAPC cell secretome ap-
pears to be safe and enhances cutaneous wound healing
by promoting skin cell proliferation and migration, bal-
ancing inflammation and improving the formation of
extracellular matrix and angiogenesis. These results pro-
vide preclinical evidence that supports the translation of
stem cell-free therapy for the treatment of wounds.
Supplementary information




ALCAM: Activated leukocyte cell adhesion molecule; CD31: Cluster of
differentiation 31; DAPI: 4′,6-Diamidino-2-phenylindole; DMEM: Dulbecco’s
modified Eagle’s medium; ECM: Extracellular matrix; FBS: Foetal bovine
serum; FGF-2: Fibroblast growth factor-2; H&E: Haematoxylin and eosin;
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HDMECs: Human dermal microvascular endothelial cells; HFFs: Human
foreskin fibroblasts; HGF: Hepatocyte growth factor; IL: Interleukin; MAPC
cells: Multipotent adult progenitor cells; MAPC-CM: Multipotent adult
progenitor cells-conditioned medium; MCP-1: Monocyte Chemoattractant
Protein-1; MMP-1: Matrix metalloproteinase; MSCs: Mesenchymal stem cells;
NGS: Normal goat serum; PBS: Phosphate-buffered saline; TIMP-1: Tissue
inhibitor of metalloproteinase; TNF-α: Tumour necrosis factor alpha;
VCAM: Vascular cell adhesion protein; VEGF: Vascular endothelial growth factor
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